CTOs on the Move

AdviNOW Medical

www.advinow.com

 
Our AI & AR powered technology reduces medical practice overhead, accelerates patient throughput, improves efficiency, and speeds up data collection.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.advinow.com
  • 10446, N 74th St
    Scottsdale, AZ USA 85258
  • Phone: 602.351.5869

Executives

Name Title Contact Details

Similar Companies

Lakeside Orthopedics

TherapeuticsMD

TherapeuticsMD is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Midwest Eye Consultants

Midwest Eye Consultants provides total eye care from eye health exams to the treatment of eye diseases. See our locations page to find an office near you.

CerpassRx

CerpassRx is dedicated to giving you the best online pharmacy experience possible. Contact us today to get your pharmacy benefit management.

Heron Therapeutics

Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.